Endobronchial ultrasound (EBUS) is a technique that is used by pulmonologists to sample (biopsy) and visualize the structure around the tracheobronchial tree. The EBUS and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) are techniques that are effective procedures to evaluate pulmonary nodules and diagnose lung infections and stages of lung cancer.
The endobronchial ultrasound biopsy market is estimated to grow in the near future. The rise in the geriatric population with increasing incidence of diseases that require endoscopic ultrasound procedures, large patient pool with respiratory disorders, and an increase in demand for minimally invasive procedures are the primary drivers that propel the growth of this market. However, the cost of medical devices and the lack of reimbursement policies in developing countries are likely to restrain the market.
Key Market Trends
Cancer Diagnosis segment is expected to dominate the market
Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. If the incidence of major cancers and population growth continue to be consistent, there may be 27.5 million new cancer cases worldwide each year, by 2040. This is an increase of 61.7% from 2018 and it is expected to be higher in males, with an increase of about 67.6%, as compared to females, with an estimated increase of 55.3%. Moreover, lung cancer is the 3rd most common cancer in the UK, accounting for 13% of all new cancer cases, and is also expected to increase. As a result of high and increasing prevalence of Cancer, the demand for Endobronchial Ultrasound Biopsy procedures is expected to increase in the future
North America is expected to dominate the market
According to the American Cancer Society’s 2019 report, an estimated 228,150 new cases of lung cancer comprising of 116,440 men and 111,710 women were estimated to have occurred in the United States (US) in 2019. Moreover, about 142,670 deaths from lung cancer (76,650 in men and 66,020 in women) were also estimated.
However, the US has a well-structured healthcare system that promotes researches and technological advancements. As a result, most global players have their presence in the US. Hence the demand for Endobronchial Ultrasound Biopsy procedures for cancer diagnosis helps the market grow.
Competitive Landscape
The majority of the Endobronchial Ultrasound Biopsy equipment is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
The endobronchial ultrasound biopsy market is estimated to grow in the near future. The rise in the geriatric population with increasing incidence of diseases that require endoscopic ultrasound procedures, large patient pool with respiratory disorders, and an increase in demand for minimally invasive procedures are the primary drivers that propel the growth of this market. However, the cost of medical devices and the lack of reimbursement policies in developing countries are likely to restrain the market.
Key Market Trends
Cancer Diagnosis segment is expected to dominate the market
Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. If the incidence of major cancers and population growth continue to be consistent, there may be 27.5 million new cancer cases worldwide each year, by 2040. This is an increase of 61.7% from 2018 and it is expected to be higher in males, with an increase of about 67.6%, as compared to females, with an estimated increase of 55.3%. Moreover, lung cancer is the 3rd most common cancer in the UK, accounting for 13% of all new cancer cases, and is also expected to increase. As a result of high and increasing prevalence of Cancer, the demand for Endobronchial Ultrasound Biopsy procedures is expected to increase in the future
North America is expected to dominate the market
According to the American Cancer Society’s 2019 report, an estimated 228,150 new cases of lung cancer comprising of 116,440 men and 111,710 women were estimated to have occurred in the United States (US) in 2019. Moreover, about 142,670 deaths from lung cancer (76,650 in men and 66,020 in women) were also estimated.
However, the US has a well-structured healthcare system that promotes researches and technological advancements. As a result, most global players have their presence in the US. Hence the demand for Endobronchial Ultrasound Biopsy procedures for cancer diagnosis helps the market grow.
Competitive Landscape
The majority of the Endobronchial Ultrasound Biopsy equipment is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned
A selection of companies mentioned in this report includes:
- ACE Medical Devices Pvt. Ltd.
- Boston Scientific Corporation
- CLINODEVICE
- CONMED Corporation
- Cook Group Incorporated
- ENDO-FLEX GmbH
- Medi-Globe Corporation
- Medtronic Plc
- Micro-Tech Endoscopy
- Olympus Corporation
Methodology
LOADING...
